Overall, the tumor-suppressing effects of YAP/TAZ seem to mainly manifest in hematological cancers, ERα-positive breast cancer, Wnt/β-catenin-driven CRCs, and lung SCCs. This evidence concerns the gene YAP1 and hematopoietic and lymphoid cell neoplasm.